Ezrin-derived peptides and pharmaceutical compositions — US9682140B2
Authors not yet confirmed · 2017 · Primary source linked above
What does this source report?
The patent distinguishes HEP1/Gepon (TEKKRRETVEREKE), its shorter fragments and the modified HP-V2 sequence GEKKRRETVEREGG. Identity and patent proposals do not establish equivalent clinical effects.
- Population and setting
- Ezrin-related patent chemistry and experimental examples
- Evidence type
- Patent / reported experiments
- Preparation
- See the original report; formulation details require verification.
- Source language
- See source; English abstract or translated patent text where available
- Title provenance
- Title as recorded in the linked source or index. A separate original-language title has not been transcribed unless shown above.
What are the limitations?
- Modified sequences and mixtures must not inherit Gepon outcomes.
- Clinical evidence appraisal remains pending.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Selected text reviewed
Source access and review scope
Selected original-source text checked; full methodological review pending.
Recorded source-check date: 2026-10-05. This date does not imply a completed systematic review.
Cite and trace this record
Original source: Author unconfirmed. Ezrin-derived peptides and pharmaceutical compositions — US9682140B2 Primary source linked above 2017.
Molekul research summary: https://molekul.io/research/rp-gepon-patent. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry